Endometrial Thickness in 1,500 Asymptomatic Postmenopausal Women Not on Hormone Replacement Therapy

2013 ◽  
Vol 75 (3) ◽  
pp. 191-195 ◽  
Author(s):  
Alex Hartman ◽  
Wendy Wolfman ◽  
Dan Nayot ◽  
Michael Hartman
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Endometrial Thickness ◽  
Hormone Replacement

The effects of conjugated equine estrogens plus cyclical dydrogesterone on serum lipoproteins and apoproteins in postmenopausal women

1988 ◽  
Vol 117 (3) ◽  
pp. 339-342 ◽  
Author(s):  
C. D. Fletcher ◽  
E. Farish ◽  
M. M. Dagen ◽  
F. Alazzawi ◽  
D. McQueen ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Hdl Cholesterol ◽  
Serum Lipoproteins ◽  
Conjugated Equine Estrogens ◽  
The Individual ◽  
Equine Estrogens

Abstract. erum lipoprotein and apoprotein concentrations were monitored for 24 weeks in 26 postmenopausal women treated with conjugated equine estrogens (0.625 mg/day) with the addition of dydrogesterone (10 mg/day) for the last 12 days of each 28 day cycle. The women had had no previous hormone replacement therapy. The estrogen plus dydrogesterone regimen caused significant (P < 0.05) increases in triacylglycerol and HDL cholesterol concentrations. Both HDL2 and HDL3 cholesterol were increased. There were no other significant changes in lipoprotein concentrations. Both apoprotein AI and apoprotein All concentrations increased significantly (P < 0.05) over the study period. The ratios of apoprotein AI to apoprotein All, apoprotein AI to HDL cholesterol and apoprotein All to HDL cholesterol did not change. At the doses employed in this study, the use of dydrogesterone as a progestogen alters the effects of conjugated equine estrogens on lipoproteins and reinforces the view that the effects of a combined HRT regimen cannot be predicted from a consideration of the effects of the individual components.

Sign in / Sign up

Export Citation Format

Share Document